Vaccination of animals against Mycobacterium bovis

Vaccination could potentially be used as a practical means of controlling bovine tuberculosis in countries in which a wildlife reservoir of the disease is present, and also in those countries which cannot afford conventional control strategies. An understanding of the processes involved in the protective immune response to tuberculosis is desirable for the rational development and testing of new vaccines for tuberculosis. The authors review current knowledge regarding the processes involved in protective immune responses to tuberculosis, much of which has been derived from studies in mice. This knowledge is discussed in relation to the problem of using vaccination to induce protective immunity in cattle, deer and wildlife. Challenge models have now been developed to test candidate vaccines in many domestic animals and wildlife species and these models are being used to evaluate tuberculosis vaccines. Most studies of the efficacy of tuberculosis vaccines in target animals have focused on the use of bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis. Recent advances in immunology and the molecular biology of mycobacteria have greatly increased the options for candidate vaccines and future studies will test new types of vaccines including new attenuated strains of M. bovis, sub-unit protein vaccines and recombinant deoxyribonucleic acid vaccines. Several of these vaccines have shown promising results when tested in small animal models. Although progress has been made in the development of vaccine delivery systems for animals, the technical problems associated with vaccination of wildlife remain a challenge.